Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2450 - A Phase I Global Trial Targeting Multiple Solid and Hematologic Malignancies through a NKG2D receptor-based CAR-T Immunotherapy

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Haematological Malignancies

Presenters

BIKASH VERMA

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

B. VERMA1, A. Awada2, P. Aftimos2, P. Lewalle3, N. Meuleman3, J. Machiels4, G. Catala5, E. Vandenneste6, J. Brayer7, D. Sallman7, S. Sahebjam8, T. Kerre9, S. Rottey10, K. Odunsi11, E.S. Wang12, U. Santanam1, C. Lonez13, D.E. Gilham13, F. Lehmann13

Author affiliations

  • 1 Immuno-oncology, Celyad, 02210 - BOSTON/US
  • 2 Oncology, Institute Jules Bordet, 1000 - Brussels/BE
  • 3 Hematology, Institute Jules Bordet, 1000 - Brussels/BE
  • 4 Oncology, Cliniques Universitaires Saint-Luc, 1200 - Brussels/BE
  • 5 Oncology, Cliniques Universitaires Saint-Luc, 1200 - Woluwe-Saint-Lambert/BE
  • 6 Hematology, Cliniques Universitaires Saint-Luc, 1200 - Brussels/BE
  • 7 Hematology, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
  • 8 Oncology, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
  • 9 Hematology, Ghent University Hospital, Ghent/BE
  • 10 Oncology, Ghent University Hospital, Ghent/BE
  • 11 Oncology, Roswell Park Cancer Institute, . - Buffalo/US
  • 12 Hematology, Roswell Park Cancer Institute, . - Buffalo/US
  • 13 Immuno-oncology, Celyad, B-1435 - Mont-Saint-Guibert/BE
More

Resources

Abstract 2450

Background

Because of its increasingly demonstrative successes, CAR-T therapy has been well recognized as one of the most promising therapies for cancer. We have developed a novel autologous CAR-T, NKR-2, incorporating the full-length human natural killer receptor NKG2D fused with the human CD3 zeta signaling domain. When expressed in T-cells, the naturally-expressed DAP10 provides the co-stimulatory signals to NKR-2 to be fully activated. NKR-2 selectively target tumor cells upon recognition of up to eight different NKG2D ligands expressed in many distinct cancer indications. In preclinical studies, NKR-2 demonstrated long-term anti-tumor activity towards multiple solid and hematologic tumors deploying multiple mechanisms of action targeting tumor cells and cells from the neo-vasculature and tumor suppressive immune environment, resulting in an adaptive response. In our recently completed Phase 1 study in hematologic cancers, a single administration of autologous NKR-2 was safe with initial signs of clinical benefit. Likewise, to overcome the operational challenges, our trial design incorporates strategies to harmonize multiple clinical and manufacturing processes while also enhancing patient safety and clinical outcomes.

Trial design

THINK trial (THerapeutic Immunotherapy with NKR-2) is a EU/US open-label Phase I study to assess the safety and clinical activity of NKR-2 therapy administered in three infusions, two weeks apart in five solid tumor indications (CRC, urothelial, TNBC, pancreatic, ovarian) and two hematologic indications (AML/MDS and MM). No lymphodepleting conditioning is required in this study. The study contains two consecutive segments. The dose escalation segment will enroll 18 patients in two separate hematologic and solid malignancy arms, and evaluate 3 dose levels of NKR-2 (3x108, 1x109 and 3x109 cells per injection) following a 3 + 3 design. The expansion segment will then enroll 96 additional patients in 7 separate cohorts for each indication with 3 steps of statistical analysis (overall futility, futility within each cohort and final evaluation). At time of submission, the trial has completed enrollment in its first cohort among solid indications.

Clinical trial identification

FDA: CYAD-N2T-002

Legal entity responsible for the study

CELYAD

Funding

CELYAD

Disclosure

B. Verma, U. Santanam, C. Lonez, D.E. Gilham, F. Lehmann: Employment with a pharmaceutical company: Employee of Celyad. A. Awada, P. Aftimos, P. Lewalle, N. Meuleman, J-P. Machiels, G. Catala, E. Vandenneste, J. Brayer, D. Sallman, S. Sahebjam, T. Kerre, S. Rottey, K. Odunsi, E.S. Wang: Corporate-sponsored research: Institute has received research finding from Celyad.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.